-
HIV/HBV coinfection: understanding the complex interactions and their impact on spontaneous HBV clearance, chronic liver damage, cirrhosis, and hepatocellular carcinoma. AIDS Rev. (IF 2.2) Pub Date : 2024-3-26 Jingwen Xiao, Yongzheng Zhang, Jia Wu, Xinping -Chen, Wei Zou
Compared to either HIV or hepatitis B virus (HBV) monoinfected individuals, HIV/HBV-coinfected individuals have a decreased probability of spontaneous HBV clearance and a greater risk of developing chronic liver damage and a faster progression to cirrhosis and hepatocellular carcinoma. This manuscript attempts to provide a comprehensive review of the landscape of current HIV/HBV coinfection research
-
Risk factors and mortality outcomes of COVID-19 in people living with HIV: a systematic review and meta-analysis. AIDS Rev. (IF 2.2) Pub Date : 2024-3-26 Mahmoud Kandeel
This study was performed to reveal the risk factors associated with mortality in people living with HIV (PLHIV) who were diagnosed with COVID-19. Studies reporting deaths among PLHIV and infected with SARS-CoV-2 were investigated. After protocol setup and registration, the extracted sources were categorized and assessed for quality. This study examined ten articles with a total of 46,136 patients.
-
HIV infection and esophageal cancer in Sub-Saharan Africa: a comprehensive meta-analysis. AIDS Rev. (IF 2.2) Pub Date : 2024-3-26 Gabriel Kamsu-Tchuente, Eugene J Ndebia
Africa hosts the highest burden of esophageal cancer (49%) and HIV (60%) worldwide. It is imperative to investigate the synergistic impact of these two diseases on African populations. This study conducted an exhaustive computerized search of databases, including Medline/PubMed, Embase, Web of Science, Scopus, Cochrane library, and African Journals Online, to identify eligible studies up to October
-
HTLV in Sweden. AIDS Rev. (IF 2.2) Pub Date : 2024-3-26 Jan Vesterbacka, Anna-Karin Svensson, Piotr Nowak
Sweden is a country with a low prevalence of human lymphotropic T-cell virus (HTLV) infection, estimated at < 0.005%, but the infection rate is notably higher in specific risk groups such as HTLV-2 among intravenous drug users (IVDU) and people originating from HTLV-1 highly endemic areas. Thus, in the most recent study from 2012, the prevalence of HTLV-2 among IVDU in Stockholm was 3.2%. However,
-
Early and contemporary drivers of the HIV-1 group M pandemic. AIDS Rev. (IF 2.2) Pub Date : 2024-03-05 Jude P Brennan-Calland
HIV emerged silently taking time to spread and become visible only through geographically isolated clusters of life-threatening immunodeficiency, known as AIDS since the early 80s. The clusters of infection expanded, overlapping to evolve into a pandemic that is ongoing and almost as silent. Phylogenetic analysis places the emergence of HIV-1 group M, the subtype responsible for the pandemic, in the
-
Comparison on treatment outcomes of patients enrolled on anti-retroviral therapy at different levels of the health-care system in a high HIV/AIDS setting. AIDS Rev. (IF 2.2) Pub Date : 2024-1-11 Bokwena Moali, Lebapotswe B Tlale, Bornapate Nkomo, Moses Otieno, Nathanael Sirili, Marius Nsoh, Avelina Mgasa, Anissette Ngum-Busi, Ketshepile Taylor, Nokuthula Majingo, Esther Seloilwe, Yohana Mashalla
HIV/AIDS prevalence in Botswana is amongst the highest in the world and remains a significant public health problem. however, the introduction of anti-retroviral therapy (ART) lead to a significant reduction in morbidity and mortality. Decentralization of anti-retroviral therapy has improved access to treatment for people living with HIV. Treatment outcomes for patient initiated on treatment at different
-
Prevalence and risk factors for HIV infection in truck drivers: a systematic review of global evidence. AIDS Rev. (IF 2.2) Pub Date : 2024-1-11 SeyedAhmad SeyedAlinaghi, Ramin Shahidi, Parisa Matini, Pegah Mirzapour, Ghazal Arjmand, Iman Amiri-Fard, Haleh Siami, Soudabeh Yarmohammadi, Esmaeil Mehraeen, Omid Dadras
Transporting and driving long distances might be associated with an increased risk of contracting HIV in truck drivers, which is recognized as a link to network transmission of HIV among this population. The present study aims to systematically review the prevalence and risk factors of HIV infection in truck drivers globally. A comprehensive search of the databases of Embase, PubMed, Scopus, and Web
-
HTLV European Research Network 2023: the silent pandemic of HTLV-1 infection. AIDS Rev. (IF 2.2) Pub Date : 2023-10-26 Carmen de Mendoza,Ana Treviño,Vicente Soriano
-
Mental health crisis in the youth and rebound in sexually transmitted infections. AIDS Rev. (IF 2.2) Pub Date : 2023-07-31 Vicente Soriano,Joaquín González-Cabrera
-
Systematic review and meta-analysis of the global prevalence of sexually transmitted infections in people living with HIV and associated risk factors. AIDS Rev. (IF 2.2) Pub Date : 2023-01-01 Mina Ebrahimi,Nayer Mehdizad,Fatemeh Yeganeh-Sefidan,Hanie Safarpour,Abdol S Pagheh,Amir Pouremamali,Somayeh Shiralizadeh,Ali Ghodrati,Sana Jafari,Firooz Shahrivar,Siamak Heidarzadeh,Mahboobeh Montazeri,Mohammad Yousef-Memar,Sonia M Rodrigues-Oliveira,Maria de-Lourdes-Pereira,Apostolos Beloukas,Kareem Hatam-Nahavandi,Aleksandra Barac,Milad Shirvaliloo,Ehsan Ahmadpour
People living with HIV (PLWH) constitute a vulnerable population for acquiring additional sexually transmitted infections (STIs). This study was conducted to provide a summary of the evidence on the global prevalence of STIs in PLWH with an emphasis on infectious agents, diagnostic methods, and related risk factors. PubMed, Scopus, and Web of Science were systematically searched to include records
-
Rebound in sexually transmitted infections after the COVID-19 pandemic. AIDS Rev. (IF 2.2) Pub Date : 2023-01-01 Vicente Soriano,Hilario Blasco-Fontecilla,Lucía Gallego,José V Fernández-Montero,Carmen de Mendoza,Pablo Barreiro
Sexually transmitted infections (STIs) have become the second in the global rating of infectious diseases after respiratory infections. Globally, over 1 million, new STI is diagnosed every day. Although four conditions are the most representative and of obligatory declaration (gonorrhea, syphilis, chlamydia, and human immunodeficiency virus [HIV]), there are many other prevalent STI, including trichomona
-
Mitochondrial damage as cause of long COVID. AIDS Rev. (IF 2.2) Pub Date : 2023-01-01 Ilduara Pintos,Vicente Soriano
-
The impact of the M184V resistance mutation on treatment outcomes in patients with HIV infection: a systematic review and meta-analysis. AIDS Rev. (IF 2.2) Pub Date : 2023-01-01 Mahmoud Kandeel
HIV is a global deliberating infectious disease. Of note, more than 36 million people living with HIV (PLHIV) with approximately newly diagnosed 1.5 million cases annually. M184V is a single base mutation in the highly conserved YMDD domain of reverse transcriptase (RT). It is one of the most encountered resistances associated with mutations to nucleoside RT inhibitors. There were continuous efforts
-
The use of 'sex' and 'gender' in medical research. AIDS Rev. (IF 2.2) Pub Date : 2023-01-01 Carlos Chiclana-Actis,Vicente Soriano
There is a widespread practice of using 'sex' and 'gender' interchangeably. The World Health Organization considers that they are not. It defines sex as a set of chromosome-dependent biological variables that show unique hormone profiles and anatomy. Conversely, gender refers to socially constructed sex attributions with differential roles, behavioral expressions, identity, etc. Researchers and institutions
-
HIV patients' bone loss before and after antiretroviral treatment and its possible mechanisms. AIDS Rev. (IF 2.2) Pub Date : 2023-01-01 Pei-Min Zheng,Yu-Qing Xie,Shi-Fan Lin,Le Zou,Zhi-Hua Huang,Zhi-Ping Zhang
HIV infection has been reported to cause bone loss and a higher risk of fracture. Under normal conditions, bone metabolism is regulated by mesenchymal cells, osteoclasts differentiated from mononuclear macrophages, osteoblasts, and their expression of regulatory factors, such as receptor activator of nuclear factor-kappa B ligand (RANKL), M-SCF, and transforming growth factor-beta. The balance between
-
The use of the brief symptom inventory among youth living with HIV: a scoping review. AIDS Rev. (IF 2.2) Pub Date : 2023-01-01 Natasha Richmond,Alyssa Steinbaum,Nicholas Tarantino,Nidhi Bhaskar,Laura Whiteley,Jacob J van den Berg
The brief symptom inventory (BSI), a 53-item measure that assesses psychological distress, is a popular tool for measuring mental health symptoms among youth living with HIV (YLH) in the United States (US); however, it has been used inconsistently with this population. This scoping review summarizes discrepancies in the use of the BSI to identify opportunities to improve systematism and make recommendations
-
Association between genital mycoplasmas (Ureaplasma urealyticum and Mycoplasma hominis) and HIV infection: a systematic review and meta-analysis. AIDS Rev. (IF 2.2) Pub Date : 2023-01-01 Safa Boujemaa,Gurparsad Singh-Suri,Gurleen Kaur
Several studies have reported the occurrence of genital mycoplasmas (Ureaplasma urealyticum, Mycoplasma hominis, Mycoplasma genitalium, and Mycoplasma fermentans) among human immunodeficiency virus (HIV)-infected patients, but findings are conflicting. The aim of this systematic review and meta-analysis was to assess the association of U. urealyticum and M. hominis with HIV infection. We searched seven
-
The new profile of psychiatric disorders in patients with HIV infection. AIDS Rev. (IF 2.2) Pub Date : 2023-01-01 Lucía Gallego Deike,Pablo Barreiro,Blanca Reneses
Nowadays, HIV infection is largely considered as a chronic condition rather than a deadly disease, given that effective antiretroviral treatment allows almost complete and persistent suppression of viral replication and restoration of nearly normal CD4+ T-cell counts. Being HIV a "condition", we imply that other illnesses are more frequently seen in persons living with HIV (PLHIV), among which mental
-
The management of polypharmacy in people living with HIV. AIDS Rev. (IF 2.2) Pub Date : 2023-01-01 Sergio Marin,Carles Quiñones,Carla Codina-Jiménez,Ester Valls,Eva Terricabras,Lidia Estrada,Glòria Cardona,Àngels Andreu
Antiretroviral therapy (ART) has modified the prognosis of HIV which has evolved into a chronic condition. People living with HIV (PLWH) are living longer presenting an increased number of comorbidities leading to polypharmacy. Literature on the prevalence, associated factors, drug-drug interactions (DDIs), effects on ART-outcomes, geriatric conditions, and nutritional status together with health-interventions
-
Coinfection with Viral Hepatitis in HIV patients in 2023. AIDS Rev. (IF 2.2) Pub Date : 2023-01-01 Pablo Barreiro,Víctor Moreno-Torres,Vicente Soriano
-
Viral hepatitis in persons living with HIV in the post-COVID era. AIDS Rev. (IF 2.2) Pub Date : 2023-01-01 Vicente Soriano,Víctor Moreno-Torres,Carmen de Mendoza,Octavio Corral,Pablo Barreiro
Coinfection with hepatitis viruses A to E is frequent in persons living with HIV (PLWH) and causes significant morbidity and mortality. Oro-fecal transmissible hepatitis A and E mostly produce acute self-limited episodes in poor income regions and in non-vaccinated travelers. In high-income countries, outbreaks of hepatitis A occur in men having sex with men (MSM) and chronic hepatitis E is occasionally
-
Antiretroviral therapy and weight gain in antiretroviral treatment-experienced HIV patients: A review. AIDS Rev. (IF 2.2) Pub Date : 2023-01-01 Emilie Dupont,Jean Cyr Yombi
The risk of developing non-AIDS events (NAEs) remains higher in persons living with HIV-1 (PLWH) compared to the general population despite progress made in the treatment by antiretroviral (ARV). Particular attention is therefore given to the management of risk factors associated with NAEs during the follow-up of PLWH, including overweight. Factors associated with weight gain in PLWH are multifactorial
-
Envisioning hepatitis delta cure without functional hepatitis B cure. AIDS Rev. (IF 2.2) Pub Date : 2022-12-28 Vicente Soriano,Carmen de Mendoza,Pablo Barreiro
-
Is SARS-CoV-2 the only cause of long-COVID? AIDS Rev. (IF 2.2) Pub Date : 2022-12-28 Ilduara Pintos-Pascual,Victor Moreno-Torres,Fatima Ibánez-Estéllez,Pilar Corrales-Rodriguez,Ana Treviño,Manuel Corpas,Octavio Corral,Vicente Soriano,Carmen de Mendoza
Around 10% of adults infected with SARS-CoV-2 that survive a first episode of COVID-19 appear to experience long-term clinical manifestations. The signs and symptoms of this post-acute COVID-19 syndrome (PACS) include fatigue, dyspnea, joint pain, myalgia, chest pain, cough, anosmia, dysgeusia, headache, depression, anxiety, memory loss, concentration difficulties, and insomnia. These sequelae remind
-
Sarcopenia in people living with HIV. A review. AIDS Rev. (IF 2.2) Pub Date : 2022-08-09 Paola Conde-Higuera, José J Garduño-García, Alfonso J Cruz-Jentoft, Gloria G Peña-Ordónez, Gabriel G Huitrón-Bravo
The aim of this review is to know the current status of sarcopenia in people living with acquired immunodeficiency virus, as well as predictors, prevalence, and associated factors. Searches were done in PubMed, Scielo, and ScienceDirect databases (January 2010 to August 2021), using predefined search terms. Prevalence, intervention, and meta-analysis studies investigating sarcopenia or muscle mass
-
HIV and liver disease. AIDS Rev. (IF 2.2) Pub Date : 2022-7-29 Jordi Navarro
Liver-related diseases are associated with the high levels of morbidity and mortality in people living with HIV. Between 13% and 18% of all-cause mortality in HIV-infected patients involves a liver-related damage, this being one of the main causes of death not related to acquired immunodeficiency syndrome (AIDS). People living with HIV, even when the disease is under control, are more likely to develop
-
HIV and aging, biological mechanisms, and therapies: What do we know? AIDS Rev. (IF 2.2) Pub Date : 2022-7-29 Tomás M Grosso, José Alcamí, José R Arribas, Marta Martín, Irini Sereti, Philip Tarr, Pedro Cahn, Bonaventura Clotet, Omar Sued, Eugenia Negredo
Aging, a time-dependent loss of physiological function, and its drivers are turning into a significant topic of researchas the population's mean age increases. Epigenetic alterations, telomere shortening or dysfunction, mitogenic stress,oxidative stress, or accumulation of DNA damage can drive the cell to senescence a permanent cell cycle arrest sometimes associated with a secretory phenotype and inflammatory
-
International outbreak of monkeypox in men having sex with men. AIDS Rev. (IF 2.2) Pub Date : 2022-04-01 Vicente Soriano,Octavio Corral
-
Humanized mouse models for preclinical evaluation of HIV cure strategies. AIDS Rev. (IF 2.2) Pub Date : 2022-05-27 Sally Fraker, Benjamin Atkinson, Alonso Heredia
Although the world is currently focused on the COVID-19 pandemic, HIV/AIDS remains a significant threat to public health. To date, the HIV/AIDS pandemic has claimed the lives of over 36 million people, while nearly 38 million people are currently living with the virus. Despite the undeniable success of antiretroviral therapy (ART) in controlling HIV, the medications are not curative. Soon after initial
-
News from CROI 2022 - caveats using antiretrovirals as HIV prophylaxis. AIDS Rev. (IF 2.2) Pub Date : 2022-04-01 Pablo Barreiro,Vicente Soriano
-
-
Research progress on HIV-1 immune escape mechanisms. AIDS Rev. (IF 2.2) Pub Date : 2022-10-25 Yuanxi Meng,Jiaqian Zhong,Yanhan Lv,Wei Zou
Although highly active antiretroviral therapy has transformed HIV-1 infection into a manageable chronic disease, the development of an effective vaccine is still an important and challengeable research field of HIV-1 treatment. The challenge arises from an enormous diversity of HIV-1 strains and their rapid evolution ahead of effective immune responses. HIV-1 evasion from host immunity contributes
-
Unexplained hepatitis in children after lifting COVID-19 pandemic restrictions. AIDS Rev. (IF 2.2) Pub Date : 2022-04-01 Pablo Barreiro
-
Malignancies in people living with HIV. AIDS Rev. (IF 2.2) Pub Date : 2022-03-23 Qiqiang Zhou, Wei Li, Lingbo Xia, Ruixiang Zou, Xinping Chen, Wei Zou
Almost 40 years have passed since the first case of what is known as AIDS was documented. In these 40 years, AIDS has always been a research challenge and hot spot. Researchers and scientists have made tremendous progress in basic and clinical research on HIV. In particular, the widespread use of antiretroviral therapy (ART) has made it less of a deadly disease today and more of a manageable one. In
-
A greater virulent HIV-1 subtype B variant has circulated in The Netherlands since the 1990's. AIDS Rev. (IF 2.2) Pub Date : 2022-03-01 Ana Treviño,Vicente Soriano
-
Relationship between cytokine storm and SARS-CoV-2 infection's worsening. AIDS Rev. (IF 2.2) Pub Date : 2022-10-25 Baya Guermouche,Majda Dali-Sahi,Nouria Dennouni-Medjati,Youssouf Kachekouche,Hafida Merzouk
-
Oral antivirals for the prevention and treatment of SARS-CoV-2 infection. AIDS Rev. (IF 2.2) Pub Date : 2022-01-24 Vicente Soriano, Carmen de-Mendoza, Benson Edagwa, Ana Treviño, Pablo Barreiro, José V Fernandez-Montero, Howard E Gendelman
Vaccines and antivirals are the classical weapons deployed to contain, prevent, and treat life-threatening viral illnesses. Specifically, for SARS-CoV-2 infection, vaccines protect against severe COVID-19 disease manifestations and complications. However, waning immunity and emergence of vaccine escape mutants remains a growing threat. This is highlighted by the current surge of the omicron COVID-19
-
Risk factors associated with pulmonary arterial hypertension among HIV-infected adults: A meta-analysis and systematic review. AIDS Rev. (IF 2.2) Pub Date : 2022-01-13 Ying Liu, Junyan Han, Bei Li, Jing Xiao, Leidan Zhang, Hongxin Zhao
Pulmonary arterial hypertension (PAH) occurs more frequently in patients with HIV infection than in general population. The predictive value of HIV-related factors and traditional cardiovascular factors with PAH is inconsistent across studies. The objective is to determine the roles of HIV-related risk factors and traditional cardiovascular risk factors in the development of PAH in adults with HIV
-
Central nervous system disorders in HIV-infected individuals using distinct antiretroviral drugs. AIDS Rev. (IF 2.2) Pub Date : 2022-1-5 Álvaro Mena
Neuropsychiatric disorders and central nervous system-related symptoms are very common in people with HIV and can have a very negative impact on their quality of life and worsen the prognosis of the disease. These disorders are multifactorial in origin, but may be triggered or worsened by the use of certain antiretroviral treatments. This paper reviews the epidemiology of neuropsychiatric disorders
-
Study of quality of life and depression in people living with HIV/AIDS in India. AIDS Rev. (IF 2.2) Pub Date : 2022-1-5 Deepak Jain, Y M Pavan Kumar, V K Katyal, Promil Jain, Jay P Kumar, Shreya Singh
The aim of this study was to assess the quality of life (QOL) and the severity of depression in people living with HIV/AIDS (PLWHA) and investigate its correlates. This was a cross-sectional study on 700 PLWHA in India. World Health Organization QOL HIV (WHOQOL HIV-BREF) and Patient Health Questionnaire-9 (PHQ-9) were used to assess QOL and depression in PLWHA, respectively. The study population was
-
Less hepatic decompensation events but rising liver cancer in hepatitis B patients on long-term nucleos(t)ide therapy. AIDS Rev. (IF 2.2) Pub Date : 2022-01-01 Ana Treviño,Vicente Soriano
-
COVID-19 vaccination in people living with HIV: current data and perspectives. AIDS Rev. (IF 2.2) Pub Date : 2022-01-01 Roland Thomas,Jean Cyr Yombi
There is no correlation between HIV per se and other risk factors for severe COVID-19 disease. Pivotal studies have shown that vaccination is one of the effective ways to prevent severe COVID-19 illness in the general population. Studies on people living with HIV (PLWH) are scarce. The majority of these studies with mRNA (BNT126b2 and mRNA-1273) and adenovirus vector (Ad26.COV2.2 and ChAdOx1) vaccines
-
The role of nurses in the prevention of anal cancer in HIV-infected men having sex with men - a focus on papillomavirus vaccination and anal cytology screening. AIDS Rev. (IF 2.2) Pub Date : 2022-01-01 Jèssica Muñoz-Rodríguez,Lucia Millán-Revilla
Anal cancer is a common disease in men who have sex with men (MSM) with HIV infection and is associated with human papilloma virus (HPV) infection, which is very prevalent in this population. Advanced anal cancer has an aggressive treatment, with a high risk of producing an impaired quality of life. In cases of late diagnosis, mortality remains elevated. Based on these findings, it is a priority to
-
Alert for polio outbreaks in developed countries. AIDS Rev. (IF 2.2) Pub Date : 2022-01-01 Vicente Soriano
-
The opioid epidemic during the COVID-19 pandemic: Impact on HIV and HCV control. AIDS Rev. (IF 2.2) Pub Date : 2021-12-29 Ana Treviño,Vicente Soriano
-
Another patient has cured HIV infection. AIDS Rev. (IF 2.2) Pub Date : 2021-12-29 Carmen de Mendoza,Vicente Soriano
-
Nutritional assessment in the HIV-infected older population receiving antiretroviral therapy. AIDS Rev. (IF 2.2) Pub Date : 2021-12-22 Tippawan Siritientong, Daylia Thet
Malnutrition is a pronounced public health issue which often seems underestimated in the older people living with HIV (PLWH) virus infection. PLWH are highly vulnerable to nutritional problems resulting from agingrelated deterioration, disease itself, and adverse effects of antiretroviral therapy (ART). The comprehensive nutritional assessments are necessary to perform routinely in this population
-
Mobile applications in HIV self-management: A systematic review of scientific literature. AIDS Rev. (IF 2.2) Pub Date : 2021-10-29 Esmaeil Mehraeen, Seyed A Seyed-Alinaghi, Zahra Pashaei, Pegah Mirzapour, Alireza Barzegary, Farzin Vahedi, Kowsar Qaderi, Marcarious M Tantuoyir, Zahra Nazeri, Amirali Karimi, Mohammad Mehrtak, Mohammad Heydari
Self-management through mHealth by mobile apps creates new opportunities for people living with HIV (PLHIV) for integrated and accurate management. Our study focused on current evidence on HIV selfmanagement mobile applications to identify and assess their objective, infrastructure, and target populations. A systematic review was conducted on studies that use apps to improve self-management among HIV-positive
-
New insights into the genetics of same-sex behavior. AIDS Rev. (IF 2.2) Pub Date : 2021-10-04 Lucia Gallego,Manuel de Santiago,Vicente Soriano
-
A systematic review evaluating HIV prevalence among conflict-affected populations, 2005-2020. AIDS Rev. (IF 2.2) Pub Date : 2021-06-02 Divya Mishra, Kelli O'Laughlin, Paul Spiegel
Historically, there has been concern that conflict may exacerbate the HIV epidemic. We conducted a systematic review to examine HIV prevalence in conflict-affected populations compared to district-level or countrywide HIV prevalence. Following PRISMA guidelines, studies presenting original HIV prevalence data published between 2005 and 2020 were drawn from PubMed, Scopus, and Embase. Data extracted
-
Dolutegravir in Mexico for special populations: A cost analysis perspective. AIDS Rev. (IF 2.2) Pub Date : 2021-07-01 Banda Marco, Herrera Cristina, Reynaga Cristhian, Rangel Sigfrido, Josue Del Angel, Angel Reyes, Prudente Isidoro
Integrase strand-transfer inhibitors (INSTI) are the latest class of antiretrovirals registered in Mexico. They include raltegravir (RAL), elvitegravir/cobicistat (EVG/c), dolutegravir (DTG) and bictegravir (BIC). Along with international guidelines, Mexico adopted the use of INSTI about two years ago as initial antiretroviral therapy (ART). This is partially due to the increase in the pre-treatment
-
The Prevalence of HIV-infected Patients with Virological Suppression but a CD4+ T-cell Count of ≤ 200 Cells/mm3 after Highly Active Antiretroviral Therapy Initiation: A Meta-analysis. AIDS Rev. (IF 2.2) Pub Date : 2021-06-21 Zhihui Wu, Chunling Yang, Yuqing Ma, Yueyuan Wang, Zhenkui Zhang, Zhibin Liu, Pengyu Li, Huijun Guo, Yantao Jin
Highly active antiretroviral therapy (HAART) strongly inhibits HIV replication. However, many patients show suboptimal immune recovery (SIR), as defined by virological suppression (i.e. low viral load) with a CD4+ T-cell count of ≤ 200 cells/mm3, after HAART initiation. Here, we performed a systematic evaluation of the SIR prevalence among HIV-infected patients in cohort studies. We searched PubMed
-
COVID-19 in Madrid: Leading Pandemic Control after being the Spanish Epicenter. AIDS Rev. (IF 2.2) Pub Date : 2021-06-07 Vicente Soriano, José Vicente Fernández-Montero
The arrival of coronavirus disease (COVID-19) in Europe exploded initially in North Italy and soon thereafter at several other major European cities, including Madrid. Indeed, Madrid was the epicenter of SARSCoV-2 infection in Spain, with a dramatic surge of cases since mid-March 2020.
-
Efficacy and Safety of Triple versus Dolutegravir-based Dual Therapy in Patients with HIV-1 Infection: A Meta-analysis of Randomized Controlled Trials. AIDS Rev. (IF 2.2) Pub Date : 2021-06-03 Yuanlu Shu, Chengfeng Qiu, Xiaojun Tu, Ziwei Deng, Ye Deng, Hongqiang Wang, Xiang Zhao, Zhihua Shi
A new strategy of simplification therapy shown the unique benefits in clinical treatment, by reducing pill burden and avoid drug exposure. To provide more evidence for the strategy, we compared the efficacy and safety of dolutegravir (DTG)-containing simplified dual combination antiretroviral therapy (cART) and traditional triple cART for people living with HIV/AIDS. The meta-analysis of randomized
-
Differentials of SARS-CoV-2 Viral RNA Re-positivity in Discharged COVID-19 Patients. AIDS Rev. (IF 2.2) Pub Date : 2021-06-03 Jiliang Xia, Ying Zeng, Zhenghong Tan, Ting Chen, Weilan Hu, Shulei Shuai, Deliang Cao, Xi Zeng
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious RNA coronavirus responsible for the pandemic of the coronavirus disease 2019 (COVID-19). Recent advances in virology, epidemiology, diagnosis, and clinical management of COVID-19 have contributed to the control and prevention of this disease, but re-positivity of SARS-CoV-2 in recovered COVID-19 patients has
-
Safety of Antiretroviral Therapy in the Treatment of HIV/AIDS in Children: Systematic Review and Meta-analysis. AIDS Rev. (IF 2.2) Pub Date : 2021-06-03 Renata Szpak, Natália F Lombardi, Frederico A Dias, Helena H L Borba, Roberto Pontarolo, Astrid Wiens
The safety of using different antiretroviral therapies (ART) in pediatric HIV/AIDS patients is not well-established. Therefore, this study aimed to assess the safety of ART in children. A systematic review of randomized clinical trials (RCTs) was conducted to assess the safety of ART used by pediatric patients living with HIV/AIDS. The electronic search was conducted in PubMed and Scopus, in addition
-
Sarcopenia in Persons Living with HIV under Antiretroviral Therapy: Literature Review. AIDS Rev. (IF 2.2) Pub Date : 2021-06-03 Marcus V L Dos-Santos-Quaresma, Sandra M Lima-Ribeiro
The epidemiological profile of people living with HIV (PLWH) has expressively changed since the introduction of antiretroviral therapy (ART), from a high mortality rate to a profile similar to those living with chronic diseases. Despite the advances and effectiveness of ART, there are still various challenges to overcome, and we highlight the increased risk of sarcopenia in PLWH. This review study
-
A Systematic Review and Meta-analysis to Estimate the Time from HIV Infection to Diagnosis for People with HIV. AIDS Rev. (IF 2.2) Pub Date : 2021-06-02 Semiu O Gbadamosi, Mary Jo Trepka, Rahel Dawit, Rime Jebai, Diana M Sheehan
Timely HIV diagnosis is critical to minimizing transmission events. We sought to estimate the meantime from HIV infection to diagnosis and its temporal trend among people with HIV. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a search of MEDLINE, Embase, and Google Scholar, supplemented by a hand search of bibliographies of articles, was conducted. Study
-
"Moving Fourth": Introduction of a practical toolkit for shared decision-making to facilitate healthy living beyond HIV viral suppression. AIDS Rev. (IF 2.2) Pub Date : 2021-06-02 Adrian Curran, Joop Arends, Thomas Buhk, Mario Cascio, Eugenio Teofilo, Guido van den Berk, Giovanni Guaraldi
An extension of the UNAIDS 90-90-90 target proposes >90% of people living with HIV (PLHIV) should have good health-related quality of life (HrQoL); however, limited guidance exists. The "Health Goals for Me" framework, an individualized approach to HIV care, provides a framework to assess HrQoL. We analyzed several patient-reported outcome measures (PROMs) to develop a practical toolkit to facilitate
-
Is intermittent antiretroviral therapy a satisfactory strategy for the management of patients living with HIV? AIDS Rev. (IF 2.2) Pub Date : 2021-04-12 Thomas Roland, Jean C Yombi
Many innovations, such as long-acting agents, new delivery modalities (injectable and nanoparticles), and novel paradigms (immunotherapy or dual therapy), have been introduced to facilitate the administration of antiretroviral treatment (ART) to patients infected with HIV and improve their adherence and quality of life without altering the drugs' effectiveness. Studies have investigated the use of